anti-obesity agents

Preferred Label : anti-obesity agents;

MeSH definition : Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity.; Agents that increase energy expenditure and weight loss by neural and metabolic regulation.;

MeSH synonym : drugs, antiobesity; antiobesity agents; agents, anti-obesity; anti-obesity drugs; anti obesity drugs; drugs, anti-obesity; antiobesity drugs; agents, antiobesity; anti obesity agents; Anti-Obesity Agent; Agent, Anti-Obesity; Anti Obesity Agent; Antiobesity Agent; Agent, Antiobesity; Anti-Obesity Drug; Anti Obesity Drug; Drug, Anti-Obesity; Antiobesity Drug; Drug, Antiobesity;

Related MeSH term : Weight-Loss agents; Agents, Weight-Loss; Weight Loss Agents; Weight-Loss Drugs; Drugs, Weight-Loss; Weight Loss Drugs; Weight-Loss Drug; Drug, Weight-Loss; Weight Loss Drug;

MeSH annotation : consider also OBESITY /drug ther;

Is substance : O;

action pharmacologique : O;

Details

Origin ID

D019440;

UMLS CUI

C0376607;

ATC code(s)
- bupropion and naltrexone [ATC Code]
ATC code(s)
- antiobesity preparations, excl. diet products [ATC Code]
- antiobesity preparations, excl. diet products [ATC Code]
- bupropion and naltrexone [ATC Code]
- centrally acting antiobesity products [ATC Code]
- clobenzorex [ATC Code]
- dexfenfluramine [ATC Code]
- ephedrine, combinations [ATC Code]
- etilamfetamine [ATC Code]
- fenfluramine [ATC Code]
- mazindol [ATC Code]
- mefenorex [ATC Code]
- orlistat [ATC Code]
- peripherally acting antiobesity products [ATC Code]
- rimonabant [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
False automatic mappings
- Drug-induced obesity [ICD-10 Sub-category (who)]
Indexing information
- 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide [MeSH Supplementary Concept]
- 8-chloro-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-4,5-dihydrobenzo-1H-6-oxa-cyclohepta(1,2-c)pyrazole-3-carboxamide [MeSH Supplementary Concept]
- 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid [MeSH Supplementary Concept]
- ALB-127158(a) [MeSH Supplementary Concept]
- C3201 peptide [MeSH Supplementary Concept]
- LY2112688 [MeSH Supplementary Concept]
- MC4-NN1-0182 [MeSH Supplementary Concept]
- SN 28127 [MeSH Supplementary Concept]
- SN 29220 [MeSH Supplementary Concept]
- hydroxyframoside B [MeSH Supplementary Concept]
- jacaric acid [MeSH Supplementary Concept]
- jueming [MeSH Supplementary Concept]
- redotex [MeSH Supplementary Concept]
- setmelanotide [MeSH Supplementary Concept]
- tuberil [MeSH Supplementary Concept]
Record concept(s)
- Anti-Obesity agents [MeSH concept]
- Weight-Loss agents [MeSH concept]
See also
- obesity [MeSH Descriptor]
See also (suggested by CISMeF)
- bariatric medicine [MeSH Descriptor]
- bariatrics [MeSH Descriptor]
- diet, reducing [MeSH Descriptor]
- weight loss [MeSH Descriptor]
- weight reduction programs [MeSH Descriptor]
Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
Substance(s)
- Exenatide [MeSH Descriptor]
- Orlistat [MeSH Descriptor]
- Rimonabant [MeSH Descriptor]
- ZGN-1061 [MeSH Supplementary Concept]
- bupropion hydrochloride, naltrexone hydrochoride drug combination [MeSH Supplementary Concept]
- cetilistat [MeSH Supplementary Concept]
- oleoyl-estrone [MeSH Supplementary Concept]
- perflubron [MeSH Supplementary Concept]
UMLS correspondences (same concept)
- Medicinal product acting as antiobesity agent (product) [SNOMED CT concept]
Validated automatic mappings to BTNT
- other antiobesity drugs [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients